RxDoctor Payments Data

Viswanatha Reddy, MD

Internal Medicine · Benson, NCNPI 1184663734

Payments from drug & device makers

$13,077in general payments, 2019–2025

Across 693 payments — averaging $18.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Preventric Diagnostics, Inc.$1K
  • AbbVie$955
  • Amgen$952
  • Esperion Therapeutics, Inc.$814
  • Johnson & Johnson$769
  • Novo Nordisk$750
  • plus $8K from 53 others

What the payments were for

  • Food & beverage$13,037100%
  • Education$410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Preventric Diagnostics, Inc.2$1,183
AbbVie(2 entities)61$955
Amgen71$952
Esperion Therapeutics, Inc.16$814
Johnson & Johnson50$769
Novo Nordisk53$750
Pfizer40$621
Bayer29$535
Novartis30$491
Corcept Therapeutics14$446
Lilly USA, LLC26$392
AstraZeneca(2 entities)27$379
Merck22$378
Amarin Pharma, Inc.17$370
Sumitomo Pharma America, Inc.14$351
Daiichi Sankyo Inc.20$326
GSK25$287
Boehringer Ingelheim17$280
E.r. Squibb & Sons, L.L.C.11$217
Otsuka America Pharmaceutical, Inc.9$166
Paratek Pharmaceuticals, Inc.3$148
Sanofi-aventis U.S. LLC9$143
Nestle Healthcare Nutrition Inc.7$142
Pharmacosmos Therapeutics Inc.8$136
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$134
Mylan Specialty L.p.9$129
Astellas Pharma US Inc7$129
Biogen7$121
Corium, LLC7$114
Mannkind Corporation7$113
Eisai Inc.6$90
Kowa Pharmaceuticals America, Inc.6$84
Shield Therapeutics Inc1$81
Exact Sciences5$77
Aimmune Therapeutics, Inc.3$66
Biohaven Pharmaceuticals, Inc.4$58
Teva Pharmaceuticals USA, Inc.4$56
Genentech USA, Inc.3$51
Xeris Pharmaceuticals, Inc.3$48
Vifor Pharma, Inc.3$47
Sunovion Pharmaceuticals Inc.3$45
Biohaven Pharmaceutical Holding Company Ltd.3$42
Boston Scientific2$38
Takeda Pharmaceuticals U.S.A., Inc.2$38
Baxter Healthcare1$32
Phathom Pharmaceuticals, Inc.4$29
Hikma Pharmaceuticals USA2$27
Jazz Pharmaceuticals Inc.1$23
Scilex Pharmaceuticals Inc.1$19
Dexcom, Inc.1$19
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$19
Seqirus USA Inc1$17
Agios Pharmaceuticals, Inc.1$17
Idorsia Pharmaceuticals US Inc1$16
Verona Pharma, Inc.1$15
Antares Pharma, Inc.1$15
Melinta Therapeutics, LLC1$14
The Binding Site Inc.1$13
Supernus Pharmaceuticals, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,077 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$529,500
Medicare patients
479
Services billed
19,921

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban339$231,275
OzempicSemaglutide191$200,742
MounjaroTirzepatide140$156,388
Trelegy ElliptaFluticasone/Umeclidin/Vilanter167$138,321
XareltoRivaroxaban194$126,382
JardianceEmpagliflozin136$120,802
TrulicityDulaglutide113$114,771
LinzessLinaclotide87$59,148
GemtesaVibegron65$43,672
FarxigaDapagliflozin Propanediol55$41,844
MyrbetriqMirabegron90$38,945
Tresiba Flextouch U-200Insulin Degludec35$38,121
ProliaDenosumab22$36,731
JanuviaSitagliptin Phosphate30$33,670
Tresiba Flextouch U-100Insulin Degludec40$32,405

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$392$271,160253 claims
PfizerEliquis$621$231,275339 claims
Novo NordiskOzempic, Rybelsus$750$224,506217 claims
Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Tradjenta, Stiolto Respimat$280$200,986252 claims
GSKTrelegy Ellipta, Arexvy, Anoro Ellipta, Shingrix, Breo Ellipta$287$195,347349 claims
Johnson & JohnsonXarelto$769$126,382194 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$379$91,152168 claims
AbbVieLinzess, Restasis$955$73,858113 claims
Sumitomo Pharma America, Inc.Gemtesa$351$43,67265 claims
Astellas Pharma US IncMyrbetriq$129$38,94590 claims
AmgenProlia$952$36,73122 claims
MerckJanuvia$378$33,67030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Benson

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →